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The possibility to induce an antibody response in vitro with human lympho- 
cytes is an important prerequisite for the study of the mechanisms and of the 
genetic  control  of the immune response  in man.  A  better insight  into these 
phenomena would be of obvious clinical importance since the nature of allergic 
and  autoimmune  disorders and of immunodeficiencies could be better under- 
stood.  Antibody responses  of low magnitude  to sheep red blood cells  (SRBC) 
have been obtained with spleen cells or with syngeneic combinations of lymph 
node and peripheral blood lymphocytes  (PBL) 1 (1). Strong plaque-forming cell 
(PFC)  responses  were  obtained  when  cells  from  tonsils,  either  alone  or  in 
allogeneic combinations, were stimulated with a number of different antigens 
(2-5 and BaumShl,  S., and I. Lefkovits, unpublished results). 
For many obvious reasons the blood represents a more advantageous source of lympho- 
cytes than any surgical material. However, few reports exist of an antibody response in 
vitro to SRBC with PBL  (6,  7),  in some instances (8) dependent on a  prior stimulation 
with  allogeneic blood  lymphocytes.  In  an attempt  to  stimulate these  cells  in vitro to 
respond to SRBC we met with a  number of failures. 
Having previously observed in rabbits some peculiar features when inducing antibody 
responses in vitro with blood lymphocytes (9-11),  we decided to investigate extensively 
and systematically the conditions necessary to elicit a  good and reproducible antibody 
response in vitro with human PBL. 
In this paper we present evidence that, under appropriate conditions, human 
PBL  depleted  of an  adherent  inhibitor cell  can be  triggered to give  a  small 
antibody response.  The magnitude of this response is highly increased by an 
antigen-specific mouse T-cell factor. 
Materials  and Methods 
Preparation of  Peripheral Blood Leukocytes.  Heparinized blood obtained from healthy donors 
was treated with nylon wool according to the method of Hammond et al.  (12). Briefly 20 ml of 
whole blood  were pipetted  into a  50-ml  syringe packed with 3  g  of nylon wool  (Coop,  Basel, 
Switzerland, no. 609.002).  With the aid of the syringe plunger the blood was forced to enter the 
wool. After 45 min of incubation at 37°C the cell suspension was squeezed out of the syringe. The 
wool was washed two times with 10 ml of warm Hanks' balanced salt solution (BSS). The resulting 
Abbreviations  used in this paper:  BSS, balanced salt solution; FCS, fetal calf serum; HRBC, 
horse red blood cells; MEM,  Eagle's minimal essential medium; PBL,  peripheral blood lympho- 
cytes; PFC,  plaque-forming cells; PWM, pokeweed mitogen. 
THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE"  VOLUME  144,  1976  573 574  IN  VITRO  IMMUNIZATION  OF  HUMAN  PBL 
cell  suspension was  layered  on  a  Ficoll  (Pharmacia  Fine  Chemicals  Inc.,  Uppsala,  Sweden)- 
Urovision (Shering, Berlin, West Germany) gradient (density 1,077) and centrifuged for 40 min at 
20°C with an interface force of 400g (13). The cells at the interface were harvested and washed in 
Hanks' BSS. 
In some experiments the nylon-treated blood was mixed with pig skin gelatin (Eastman Kodak 
Co., Rochester, N. Y., no. 5247) at a final concentration of 0.6%, and the red cells were allowed to 
settle at 37°C for 30 min. The leukocyte-containing supernate was centrifuged at room tempera- 
ture, and the pellet was washed in Hanks' BSS. 
Tissue Cultures.  The cells were  suspended  at the required density in  a  modified Mishell- 
Dutton medium (14), containing 5 ×  10 -'~ M 2-mercaptoethanol, 0.01 mg/ml of adenosine, guano- 
sine, uridine, and cytosine (15) and 8% fetal calf serum (FCS) (Table 1 A). 
50  /~l  per  ml  of a  1%  SRBC  or  HRBC  suspension  were  added  as  antigen.  The  cells  were 
distributed in aliquots of 0.1 ml per well in plastic trays (Falcon Plastics, Oxnard, Calif., no. 3040) 
and incubated in a  CO2 incubator without rocking. 
After the first 24 h  of culture the cells were fed with 50 ~l per well of a  nutritional cocktail 
slightly modified from the one described by Mishell and Dutton (14) and containing 0.02 mg/ml of 
the four nucleosides and 26% FCS (Table 1 B). In some experiments the cultures were rocked at 7- 
10 cycles/min on a  rocking platform (Bellco Glass,  Inc.,  Vineland,  N.  J.)  and were kept in an 
atmosphere of 7% O~, 10% CO~, and 83% N. Some of the cultures were performed in a vol of 1 ml in 
plastic Petri dishes (Falcon Plastics, no. 3001). 
A number of experiments were also performed with the culture conditions found to be optimal 
for rabbit (9) and for monkey (unpublished results) PBL, that is the cells were suspended in RPMI 
1640 medium containing 10% FCS and incubated in 1-ml aliquots in plastic tubes (Falcon Plastics, 
no. 2003) kept in an upright position in a  CO2 incubator without any further treatment. 
Evaluation of the Antibody Response  In  Vitro.  At  the  time of harvesting four  wells  were 
pooled,  the cells washed  once  in Hanks'  BSS,  and resuspended  in  0.2  ml of Eagle's  minimal 
essential medium (MEM).  When 1-ml cultures (in tubes or dishes) were made,  duplicates were 
pooled, and the cells, after washing, were resuspended in 0.5 ml of MEM. Cells were counted and 
the viability tested with the eosin exclusion method. 
The  number of direct  (IgM)  and  indirect  (IgG)  PFC  in  the  cultures  was  assayed  using  a 
modification of the method originally described by Jerne et al.  (16) and adapted for microscope 
slides by Mishell and Dutton (14) as previously described in detail (11). Briefly, 20 ~l of a 10 mg/ml 
solution of DEAE-dextran (Pharmacia Fine Chemicals, Inc.), 20 ~l of 20% SRBC or HRBC, and 10- 
50/xl of cell suspension were added to tubes containing 0.5 ml of 0.7% agar at 46°C.  The mixture 
was poured onto microscope slides precoated with agar and allowed to solidify.  The slides were 
then incubated at 37°C for 1 h  followed by 21/2 additional h  of incubation with a  1:30 dilution of 
SRBC-absorbed guinea pig complement (Behringwerke AG,  Marburg-Lahn, West Germany) or 
with rabbit anti-human IgG diluted 1:800 in 1:30 guinea pig complement. 
The  culture  fluids  were  assayed  for  presence  of  anti-SRC  antibody  by  hemagglutination 
performed in microtiter V-shaped plates. Mercaptoethanol sensitivity of the synthesized antibody 
was checked by preincubating the culture fluids with 0.1 M 2-mercaptoethanol at 37°C for 30 min. 
Preparation of the Mouse T-Cell Factor.  T-cell factor specific for SRBC or HRBC was prepared 
in C57BL/10ScSn mice using the method described in detail by Taussig (17).  Briefly, 108 thymo- 
cytes were injected into irradiated (750 R) recipients together with 0.1 ml of 10% SRBC or HRBC. 7 
days later the spleens of the recipient animals were removed and made into single cell suspension 
in MEM (Microbiological Associates, Bethesda, Md.) with 10-20 spleen equivalents of cells per 5 
ml  of medium.  The  corresponding antigen  was  added  in  the  amount  of 0.1  ml  of 0.1%  RBC 
suspension per ml of culture, and the cells were cultured for 6 h at 37°C in an atmosphere of 5% COs 
in  air.  At  the  end  of the  culture  period  the  cells  were  spun  down,  the  cell-free  supernate 
represented our preparation of the T-cell factor. 
The freshly prepared factor was added to the human PBL at a final concentration corresponding 
to the equivalent of one mouse spleen per ml of human cell suspension. Antigen was added (0.05 ml 
of 1% suspension per ml), and the mixture was incubated in ice for 30 rain with frequent mixing. 
At the end of the incubation time the cells were centrifuged, resuspended in the same volume of 
fresh medium, and distributed in the culture vessels. LUZZATI,  TAUSSIG,  MEO,  AND  PERNIS 
TABLE I 
Ingredients for Cultures 
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(A)  Culture medium 
Triple distilled water 
Hanks' BSS (10  ×) 
Essential amino acids (50 × ) 
Nonessential amino acids (100  ×) 
Sodium pyruvate (100 x) 
Sodium bicarbonate (7.5%) 
Penicillin-streptomycin 
HEPES  (1 M) 
Glutamine (200 mM) 
Vitamins (100  × ) 
Guanosine (1 mg/ml) 
Adenosine, cytosine, uridine (1 mg/ml) 
2-mercaptoethanol  (0.01  M) 
Fetal calf serum (rehatuin) 
GIBCO* 
GIBCO* 
GIBCO* 
GIBCO* 
GIBCO* 
GIBCO* 
Microbiol$ 
GIBCO 
GIBCO 
Koch-Light§ 
Koch-Light§ 
Flukal] 
Reheis¶ 
(B)  Nutritional cocktail 
Hanks' BSS (1  ×)  GIBCO 
Essential amino acids (50  x)  GIBCO 
Nonessential amino acids (100  × )  GIBCO 
Sodium bicarbonate (7.5%)  GIBCO 
Glucose (50%)  Difco 
Glutamine (200 mM)  GIBCO 
Guanosine (1 mg/ml)  Koch-Light 
Adenosine, cytosine, uridine (1 mg/ml)  Koch-Light 
Fetal calf serum (rehatuin)  Reheis 
No.  406 
No.  113 
No.  114 
No.  136 
No.  508 
No. 507 
No.  17-737 
No. 503 
No.  112 
Batch K22502 
No. 406 
No.  113 
No.  114 
No.  508 
No.  0973-60 
No.  503 
Batch K22502 
ml 81 
ml 9 
ml 2 
ml 1 
ml 1 
ml 3.75 
ml 1 
ml 1 
ml 1 
ml 1 
ml 1 
ml 1 
ml 0.5 
ml 9 
ml 9 
ml 0.4 
ml 0.2 
ml 0.75 
ml 1 
ml 0.3 
ml 0.4 
ml 0.4 
ml 4.5 
* GIBCO, Grand Island Biological Co., Grand Island, N. Y. 
Microbiological Associates,  Bethesda,  Md. 
§ Koch-Light Lab. Ltd.,  Coinbrook Bucks, England. 
II Fluka, A. G.,  Buchs, S.  G.,  Switzerland. 
¶ Reheis Chemical Co., Chicago, Ill. 
Results 
Establishment  of Culture  Conditions.  The  experiments  performed  before 
the nylon filtration  step was introduced in the cell separation procedure gave 
negative results. After the finding of this crucial requirement, responses of low 
magnitude to SRBC could be obtained, and it became therefore possible to try to 
optimalize the culture conditions. 
Antibody  responses  could  not be  induced  when  the  cells  were  cultured  at 
different densities in RPMI 1640 medium containing 10% FCS, under conditions 
(A in Table II) which were shown to be optimal for a secondary in vitro response 
to SRBC or to streptococcal carbohydrates with rabbit PBL (9,  10) or to SRBC 
with monkey PBL  (unpublished results).  Negative results were also obtained 
when  FCS was  substituted with human AB  serum or when  different  culture 
vessels were used. With a modified Mishell-Dutton medium (B in Table II) no 
responses were obtained when the cultures were performed in plastic dishes and 
kept in an atmosphere  of 7% 02,  10% CO2,  and 83% N  with constant rocking. 576  IN  VITRO  IMMUNIZATION  OF  HUMAN  PBL 
TABLE  II 
Effect of Different Culture Variables on the In Vitro Response of 
Human PBL to SRBC 
Cell den- 
Culture 
conditions*  sity x  10  ~/ 
ml 
Vessels 
PFC/10  ~ initial cells 
day 5  day 9  day 14 
A  9.0  Trays  1  0  0 
4.5  Tubes  0  0  0 
4.5  Trays  0  0  0 
B  9.0  Dishes  0  0  0 
9.0  Trays  7  46  4 
4,5  Dishes  0  0  0 
4.5  Trays  0  0  0 
* See text for details. 
Positive results were, on the other hand, observed with the same medium when 
the cultures were performed in a vol of 0.1 ml in the wells of plastic trays. Under 
these  conditions  the  gas  mixture  and  the  rocking  did  not  seem  to  play  an 
important role, therefore, in the later experiments the cultures were kept in a 
CO., incubator without rocking. 
A  relatively high  cell density was crucial  for the induction  of the response 
(Table II). Feeding with a nutritional cocktail 24 h after initiation of the cultures 
was another important requirement (Table III). With these culture conditions a 
PFC response could be obtained which peaked at about day 8, with 30-300 PFC 
per  10" initial  cells.  Fig.  1 illustrates  the results obtained with five different 
donors. 
Plaques  were  all  of the  direct  type.  The  response  was  dependent  on  the 
presence of antigen,  controls showed very few if any PFC.  However, in more 
than 50% of the experiments no response or a very low response was obtained, 
even with donors that have previously given good results.  This was true  also 
with gelatin separated PBL. 
In the attempt to find out whether this variability is due to the presence of a 
very small number of circulating precursors able to be triggered by SRBC, we 
performed an experiment where several independent pools were assayed at each 
harvesting  day.  If the assumption was true  there  should be a  big variability 
among different pools due to sampling error.  The results reported in Table IV 
show  that  this  is  not  the  case,  in  fact,  all  the  pools  responded  and  with 
approximately the same number of plaques. 
Search  for Possibilities  to Amplify  the Response.  Experiments  were per- 
formed to investigate whether it is possible to amplify the B-cell response to the 
antigen  and hence to obtain better and more consistent results.  In a  series of 
experiments the effect of various mitogens added to the cultures together with 
the antigen was investigated.  No effect on the antibody response was observed 
when  5-20  tzg/ml  of  lipopolysaccharide  (LPS)  (Escherichia  coli LPS,  Difco 
Laboratories, Detroit, Mich., no. 3122-25) or a  1:100-1:500  dilution of pokeweed 
mitogen  (PWM)  (Grand  Island  Biological Co.,  Grand  Island,  N.  Y.,  no.  536) 
were added. LUZZATI,  TAUSSIG,  MEO,  AND  PERNIS 
TABLE  III 
Effect of Feeding with the Nutritional Cocktail on the In Vitro 
Response of Human PBL to SRBC 
Cocktail 
PFC/10  ~ initial cells 
day 6  day 7  day 8  day 9 
Yes  2  21  23  9 
No  3  0  0  0 
The  cells  were cultured  in the  modified  Mishell-Dutton  medium  at a 
density of 9 ×  106/ml in the wells of plastic trays and incubated in a CO2 
incubator without rocking. 
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FIG.  1.  Antibody response in vitro to SRBC with PBL of five different donors. 
In other experiments a modification of the cell surface with enzymes or with 
Na periodate was attempted. The cells were treated with pronase (Protease VI, 
Sigma Chemical Co., St. Louis, Mo.) at concentrations of 100, 200, or 400 ~g/ml 
or with neuraminidase (Cl. perfringens,  Worthington  Biochemical Co.,  Free- 
hold, N. J.) at concentrations of 20 or 1.5 ~g/ml, or with 1 mM NaIO4 for 20 min 
at 37°C.  The cells were then washed and put in culture with antigen or with 
antigen and PWM (final dilution 1:500). None of these treatments improved the 
response to SRBC. 
When,  on  the  other  hand,  human  lymphocytes  were  incubated  with  an 
antigen-specific mouse T-cell factor a  striking increase in the response to the 
antigen  was  observed.  Fig.  2  shows  the  plaques  obtained  when  equivalent 578  IN  VITRO  IMMUNIZATION  OF  HUMAN  PBL 
TABLE  IV 
Comparison of the Anti-SRBC Response in Different Cultures 
Donor  Ag 
Day in culture 
6  7  8  9 
B.P.  -  0,0  5,0,0  0,0,0  0,0,0 
+  21,17  85,30,47  75,12,7  6,15,66,36 
I.L.  -  3,1  0 
+  53,23  11,34 
Figures represent PFC per pool of two wells. 
FIG.  2.  PFC  to  SRBC  observed at  day  5  from cultures nontreated  (top)  and  treated 
(bottom) with mouse T-cell factor. 
volumes of nontreated and treated cultures were assayed for their response to 
SRBC. The best results were obtained when 6 ×  106/ml PBL were treated with 
the factor and cultured at the same density (Table V). With 9 x  106/ml cells the 
response was slightly lower and with 3 × 10"/ml no response whatsoever could be 
observed. 
When human PBL at a cell concentration of 6  ×  10S/ml were treated with a 
mouse T-cell factor specific for SRBC, PFC specific for the antigen could already 
be observed at day 4,  then their number increased and a  peak was reached 
around day 8 (Fig. 3). 
Parallel to the increase in PFC there was an increase in cell number. The cells 
recovered from the treated cultures were at all the times more numerous than in 
the nontreated cultures (Fig. 3).  Similar results were obtained in a number of 
different experiments  (Table  VI)  although the  height of the  response,  both 
proliferative and antibody-producing, varied from experiment to experiment, 
probably due to variations from one batch of factor to another. It is clear from LUZZATI~  TAUSSIG,  MEO,  AND  PERNIS 
TABLE  V 
Anti-SRBC Response In Vitro of Human PBL Treated with T- 
Cell Factor: Effect of Cell Concentration 
Cell input per well  x  Recovered cells per  PFC per well 
10  5  well  x  10 -s 
3  0.4  0 
6  12.4  910 
9  20.2  710 
Cells at different concentrations (3  x  10  ~,  6  x  10%  9  x  10~tml) were 
treated with the factor, centrifuged, brought to the initial volume with 
fresh medium, and cultured in 0.1-ml aliquots per well. The response 
was measured at day 6. 
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FIG.  3.  Response in vitro to SRBC of human PBL treated with mouse T-cell factor. (I -  B) 
PFC/well;  (n__-[:3)  recovered cells/well; (O---O)  recovered cells/well (control without 
factor treatment); Cell input/well 6 x  l0  s. The cultures that were not treated with the factor 
did not give PFC. 
the data shown in Table VI that a higher proliferative response accompanies a 
higher PFC response. In experiment no. 3 the controls without factor showed a 
good cell recovery and a late appearing small PFC response. 
The results presented in Table VII show that the effect of  the mouse T factor is 
antigen dependent and antigen specific. In fact a  factor induced with SRBC, 
when used alone or in presence of HRBC, did not cause any proliferative and 
antibody response. Both responses were obtained when the factor and its corre- 
sponding antigen were added to the cells.  The activity of the factor could be 
removed by  absorption  with  packed  SRBC  or  by passage  over  a  Sepharose 
column coated with a B10A anti-B10 serum (anti-H-2b). 580  IN  VITRO  IMMUNIZATION  OF  HUMAN  PBL 
TABLE  VI 
Anti-SRBC Response In Vitro With Human PBL Treated with T- 
Cell Factor:  Three Independent Experiments with the Same 
Donor 
Exp.  Day  Cells (x  10  ~)  PFC 
1  6  12.4  910 
8  14.3  1,423 
2  6  14.7  8,360 
(1.0)  (0) 
8  20.5  13,000 
(0.9)  (0) 
3  6  5.5  61 
(1.5)  (0) 
8  9.9  124 
(3.4)  (16) 
The results are given as cell yield and PFC per well. The initial input 
was 6  ×  1@ cells per well. In parenthesis, controls without factor. 
TABLE  VII 
Some Properties of the Mouse T-Cell Factor Helping the In Vitro 
Response of Human PBL 
Present in culture  Day 5  Day 8 
Cells x  Cells x 
Factor  Antigen  10_  ~  PFC  10_.~  PFC 
No  SRBC  0.7  0  0.9  0 
No  HRBC  0.7  0  0.9  0 
Yes  No  0.8  0  0.8  0 
Yes  SRBC  13.0  750  20.5  13,000 
Yes  HRBC  0.2  0  1.1  0 
Anti-H-2 Abs  SRBC  1.0  0  0.6  0 
SRC Abs  SRBC  0.8  0  1.2  0 
The results are given as cell yield and PFC  per well.  The initial cell 
input was 6  x  10  .~ cells per well. The factor was induced in presence of 
SRBC. 
The specificity of the effect was further investigated by using a mouse factor 
specific for HRBC (Table VIII). The response obtained to HRBC was rather low, 
and it was dependent on the presence of the specific antigen only at day 6, while 
at day 8 a small response to HRBC was also induced in the presence of SRBC. A 
strong stimulatory effect was seen when both antigens were used in the presence 
of HRBC factor. 
Cultured cells  were  stained  for their  content of immunoglobulins with  a 
fluorescent rabbit anti-human Ig serum. The proportion of cultured cells which 
contained Ig was in no instance higher than 2-3% and usually around 1%. The 
results of one experiment are shown in Table IX. In the treated cultures there LUZZATI,  TAUSSIG,  MEO,  AND  PERNIS  581 
TABLE  VIII 
Antigen Specificity in the Activation  of Human Lymphocytes by Mouse T-Cell 
Factors 
Type of immunogen for  Day 6  Day 8 
PFC to  PFC to 
Factor pro-  Addition to cul-  Cells  Cells 
duction  tures  (×  10 -5)  (×  10  5) 
SRBC  HRBC  SRBC  HRBC 
-  SRBC  1+5  0  0  3.4  16  0 
SRBC  SRBC  5.5  61  1  9.9  124  0 
SRBC  HRBC  1.0  0  0  2.0  0  0 
HRBC  HRBC  3.0  3  24  2.8  3  25 
HRBC  SRBC  2.2  0  0  2.5  16  22 
HRBC  HRBC and  2.5  66  14  3.7  1,011  465 
SRBC 
Results are given as cell yield and PFC per well. The initial cell input was 6  ×  105 cells per 
well. 
TABLE  IX 
Effect of Specific Mouse T-Cell Factor on Human PBL Cultured 
with SRBC 
PFC to 
Day  Factor  Cells per well  Ig  ÷ per 10  ~  cells  SRBC per 
l0  s cells 
5  -  0.7  ×  10  ~  600  0 
(3OO) 
+  13+0  ×  10  ~  1,600  577 
(1,000) 
8  -  0.9  ×  10  +  <100  0 
(<100) 
+  20.5  ×  105  27,000  6,500 
(6,000) 
11  +  10.2  ×  105  1,500  834 
(1,000) 
Ig  ÷, IgM and IgG (in parenthesis) containing cells. 
was  an  increase  in  the  number  of Ig-containing  cells  which  paralleled  the 
increase in PFC, being two to four times higher. 
The class of the antibody produced was examined; all the plaques detected in 
the present experiments were direct.  We could not detect any additional plaque 
upon treatment with a  rabbit anti-human Ig serum.  Accordingly all the anti- 
body secreted in the culture fluid and which in some experiment reached a titer 
of 1/64 in hemagglutination was mercaptoethanol sensitive. 
Discussion 
The  data presented  in this paper show that  in human PBL there  are  cells 
which,  under appropriate  conditions,  can be triggered  in vitro with SRBC  to 582  IN  VITRO  IMMUNIZATION  OF  HUMAN  PBL 
give a  specific antibody response. We report evidence that the number of such 
cells must be relatively high, in fact no fluctuation of the response was observed 
among different cultures when culturing 10  ~ cells/well, thus indicating that each 
well must have received at least one precursor cell. Triggering can occur only 
after removal of adhering inhibitor cells, which are likely to be analogous to the 
adhering inhibitor cells previously described in rabbit PBL (11). 
Unfortunately, under the conditions described, positive results were obtained 
in not more than 50% of the experiments, even when the same blood donors were 
used and even though the same procedure was always followed, the ingredients 
were from the same batch and the same operators were involved in any given 
step.  Addition  of mitogens  or  modification  of the  cell  surface  by enzymatic 
treatment  or  with  sodium  periodate  did  not  change  the  magnitude  of the 
response or the proportion of positive experiments.  On the basis of the results 
obtained  with  the  T-cell  factor  this  variability  can  perhaps  be  ascribed  to 
insufficient number of T-helper cells in human peripheral blood or to a blocking 
of their function.  In fact when human  PBL were treated with a  mouse T-cell 
factor specific for SRBC, in the presence of the corresponding antigen, a striking 
effect was observed. The magnitude of the antibody response was increased up to 
100-fold, without any change of the kinetics,  a  peak being still obtained after 
about 8 days of culture. This increase in the antibody response was paralleled by 
an increase in cell proliferation and/or cell survival, in comparison with cultures 
performed with cells not treated with the factor or treated with the factor in the 
absence of the specific antigen. 
The observation that the proportion of Ig-containing cells is not much larger 
than  the proportion of PFC indicates that the effect of the factor treatment  is 
uniquely  directed  toward  the  cells  able  to  respond  to  the  specific  antigen. 
However, as the proportion of Ig-containing cells was not higher than 1-2% of 
the cells recovered from the cultures, the question arises as to what all the other 
cells are.  It may be that they represent human helper T cells which may also 
come into play as will be discussed later. 
The mouse factor used in the present investigation  was obtained under the 
conditions previously shown to yield a product of educated murine thymocytes 
able to cooperate with bone marrow cells in vivo (17) even in spite of I-region 
incompatibility  (18).  It was postulated that  the factor has an  antigen-specific 
variable section joined to an H-2-1inked gene product (19). 
The molecule'active in helping the human PBL to give an anti-SRBC response 
displays basic similarities in that it can be removed by absorption with SRBC or 
by treatment  with  anti-H-2  serum.  There  are  many  reports  indicating  that 
various factors produced by T cells, either after contact with a specific antigen or 
after stimulation by allogenic cells or mitogens,  can replace the requirements 
for T  cells in antibody formation  (20-23).  These factors may or may not have 
antigen  specificity and  in  many  instances  have been shown to act across an 
allogenic or even xenogenic histocompatibility barrier (24, 25, and Estroff, T. W. 
and P. Galanaud,  personal communication). 
It has been shown that the mouse T-cell factor used in the present work binds 
to human  cells and  that when factors specific for synthetic antigens,  such  as 
(T,G)-A--L and (Phe,G)-A--L, are used, donors can be found whose cells do not LUZZATI,  TAUSSIG,  MEO,  AND  PERNIS  583 
bind either one or the other or both factors (Taussig,  M.  J.  and D.  Bernocco, 
unpublished  results).  On  the  other  hand,  it  is  not  known  if the  binding  is 
exclusively to B cells, through a specific acceptor molecule, as postulated for the 
mouse system (19). In fact it could also be that human T cells are involved in the 
binding and that this in turn causes them to produce a human factor which may 
or  may  not  be  antigen  specific.  If this  were  the  case  many  of the  non-Ig- 
containing  cells recovered from the cultures could be human T  cells actively 
collaborating to the anti-SRC response. 
Participation of human T cells to the in vitro response in the presence of the 
mouse T-cell factor could perhaps  explain the mutually potentiating response 
obtained when two possibly cross-reacting antigens are present in culture at the 
same time, with a mouse factor specific for one of them (Table VIII). Consistent 
with this view is also the observation that when (T,G)-A--L is added with SRBC 
to cultures of human cells treated with SRBC-specific factor a response to (T,G)- 
A--L is also obtained (unpublished results). 
The question now arises why human circulating lymphocytes, more than 60% 
of which are T cells (26), are difficult to induce to an in vitro antibody response, 
unless  supported  by  a  mouse  factor  and  its  specific  antigen  or  by a  mixed 
lymphocyte culture reaction (8). In this respect it is noteworthy that the require- 
ment for an additional help is not absolute and that under certain conditions, 
which we have failed to standardize,  a sizable antibody response can be induced 
in cultures of human PBL solely in presence of the antigen.  Additional factors 
might  counteract  unfavorable  conditions  due  to  functional  heterogeneity  of 
peripheral T cells in terms of ratios of helper and inhibitory effects. 
It is obvious that further experiments  are required to elucidate the mecha- 
nisms that are at the basis of the antibody response in vitro described in this 
paper. However, we believe that this system, perhaps after some improvement 
and extension to other antigens, may allow a  study of the immune response in 
man. 
Summary 
A culture system is described which provides adequate conditions for in vitro 
immunization of human peripheral blood lymphocytes to heterologous erythro- 
cytes. Making use of this method we could obtain,  with a  number of different 
donors, an antibody response which peaked at about day 8 of culture with 30-300 
plaque-forming cells (PFC) per 106 input lymphocytes. However, in a number of 
experiments poor or negative results were obtained, even with donors that had 
previously given good response. This variability in the results was shown not to 
be due to a  too low number of precursor cells present  in the blood and could 
be overcome by treating the cells, before initiation of the culture, with a factor 
produced by mouse T cells educated to sheep erythrocytes (SRBC). Under these 
conditions a PFC response was obtained which peaked at about day 8 and which 
in some experiments could be as high as 20,000 PFC per 106 input lymphocytes. 
Paralleling the increase in PFC was an increase in cell number. The cells recov- 
ered from the treated cultures were at all times more numerous than in the non- 
treated cultures. The height of both the proliferative and antibody-producing re- 584  IN  VITRO  IMMUNIZATION  OF  HUMAN  PBL 
sponses varied from experiment to experiment,  a  higher proliferative response 
accompanying a  higher PFC response. 
Although the mechanisms that are at the basis of the antibody response in 
vitro described in this paper still need to be clarified, this system may become a 
useful tool in studying the immune response in man. 
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